Stocks · News reference

Soligenix To Apply For Bundibugyo Ebola Vaccine Development Funding

Jun 8, 2026, 11:34 AMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 7, 2026, 11:49 AMBenzinga Newsdesk
Soligenix Q2 EPS $(0.12) Beats $(0.15) Estimate
Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 85.37 percent increase over losses of $(0.82) per share from the same
Read original at benzinga
SNGX
SEC EDGARJun 26, 2026, 8:06 PMSEC EDGAR
8-K filing — SOLIGENIX, INC. (SNGX)
Filed: 2026-06-26 AccNo: 0001104659-26-078251 Size: 199 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgar
SNGX
BenzingaJun 8, 2026, 11:30 AMPrnewswire
Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine
Soligenix (NASDAQ: SNGX) announced it is applying for vaccine development funding from the Coalition for Epidemic Preparedness Innovations (CEPI) for a Bundibugyo virus vaccine. The company, in collaboration with University of Hawaiʻi researchers, has developed thermostable filovirus vaccines that demonstrated up to 100% protection in non-human primates. The application leverages Soligenix's ThermoVax platform technology and addresses the ongoing Bundibugyo outbreak in the Democratic Republic of Congo and Uganda.
Read original at benzinga
SNGX